131l-omburtamab radioimmunotherapy for neuroblastoma central nervous system/leptomeningeal metastases. website (U.S. National Library of Medicine). Last updated March 11, 2019. Accessed May 29, 2019.

About DIPG. DIPG Registry website. Accessed November 13, 2018.

Agarwal A, Ressler D, Snyder G. The current and future state of companion diagnostics. Pharmgenomics Pers Med. 2015;8:99-110. doi: 10.2147/PGPM.S49493.

Ahmed M, Cheng M, Cheung IY, Cheung N-K. Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody. Oncoimmunology. 2015;4(4):e989776-1-e989776-11. doi: 10.4161/2162402X.2014.989776.

Ahmed M, Cheng M, Zhao Q, et al. Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3. J Biol Chem. 2015;290(50):30018-30029.
doi: 10.1074/jbc.M115.679852.

Ahmed M, Hu J, Cheung N-K. Structure based refinement of a humanized monoclonal antibody that targets tumor antigen disialoganglioside GD2. Front Immunol. 2014;5:372. doi:  10.3389/fimmu.2014.00372.

American Cancer Society website. Accessed May 29, 2019.

Brain tumor. Mayo Clinic website. Accessed May 29, 2019.

Cheal SM, Xu H, Guo HF, Zanzonico PB, Larson SM, Cheung N-K. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using a IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Mol Cancer Ther. 2014;13(7):1803-1812. doi: 10.1158/1535-7163.MCT-13-0933.

Cheng M, Ahmed M, Xu H, Cheung N-K. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy. Int J Cancer. 2015;136(2):476-486. doi: 10.1002/ijc.29007.

Cheung N-K, Ostrovnaya I, Kuk D, Cheung IY. Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy. J Clin Oncol. 2015;33(7):755-763. doi: 10.1200/JCO.2014.57.6777.

Companion diagnostics. U.S. Food and Drug Administration website. Accessed February 8, 2019.

Corbin ZA, Nagpal S. Leptomeningeal metastases. JAMA Network website. Accessed July 1, 2019.

Davidoff AM. Neuroblastoma. Semin Pediatr Surg. 2012;21(1):2-14. doi: 10.1053/j.sempedsurg.2011.10.009.

Desmoplastic small round cell tumors (DSRCT) diagnosis. Memorial Sloan Kettering Cancer Center website. Accessed November 11, 2018.

Diffuse intrinsic pontine glioma (DIPG). Dana-Farber Boston Children’s Cancer and Blood Disorders Center website. Accessed May 29, 2019.

Dobrenkov K, Cheung N-K. GD2-targeted immunotherapy and radioimmunotherapy.  Semin Oncol. 2014;41(5):589-612. doi: 1053/j.seminoncol.2014.07.003.

Ha J-H, Kim J-E, Kim Y-S. Immunoglobulin Fc heterodimer platform technology: from design to applications in therapeutic antibodies and proteins. Front Immunol. 2016;7:394. doi: 10.3389/fimmu.2016.00394.

Hashimoto Y, Penas-Prado M, Zhou S, et al. Rethinking medulloblastoma from a targeted therapeutics perspective. J Neurooncol. 2018;139(3):713-720. doi: 10.1007/s11060-018-2917-2.

Hoseini SS, Guo H, Wu Z, Hatano MN, Cheung N-K. A potent tetravalent T-cell–engaging bispecific antibody against CD33 in acute myeloid leukemia. Blood Advances. 2018;2(11):1250-1258. doi: 10.1182/bloodadvances.2017014373.

Kramer K, Kushner B, Heller G, Cheung N-K. Neuroblastoma metastatic to the central nervous system: the Memorial Sloan-Kettering Cancer Center experience and a literature review. Cancer. 2001;91(8):1510-1519. doi: 10.1002/1097-0142(20010415)91:8<1510::AID-CNCR1159>3.0.CO;2-1.

Kramer K, Kushner BH, Modak S, et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol. 2010;97(3):409-418. doi: 10.1007/s11060-009-0038-7.

Larson SM, Carrasquillo JA, Cheung N-K, Press O. Radioimmunotherapy of human tumors. Nat Rev Cancer. 2015;15(6):347-360. doi: 10/1038/nrc3925.

Luther N, Zhou Z, Zanzonico P, et al. The potential of theragnostic 124I-8H9 convection-enhanced delivery in diffuse intrinsic pontine glioma. Neuro Oncol. 2014;16(6):800-806. doi: 10.1093/neuonc/not298.

Medulloblastoma. National Cancer Institute Center for Cancer Research website. Accessed May 7, 2019.

Naxitamab for high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow. website (U.S. National Library of Medicine). Last updated June 18, 2019. Accessed June 18, 2019.

Nayar G, Ejikeme T, Chongsathidkiet P, et al. Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget. 2017;8(42):73312–73328. doi: 10.18632/oncotarget.20272.

Neuroblastoma. St. Jude Children’s Research Hospital website. Accessed July 1, 2019.

Osteosarcoma – childhood and adolescence: symptoms and signs. Cancer.Net website. Accessed May 29, 2019.

Stallard J. Drug delivery approach shows promise for treating a deadly brain tumor in children. Memorial Sloan Kettering Cancer Center website. June 2018. Accessed May 29, 2019.

Thomas R, Rajeswaran G, Thway K, Benson C, Shahabuddin K, Moskovic E. Desmoplastic small round cell tumour: the radiological, pathological and clinical features. Insights Imaging. 2013;4(1):111-118. doi: 10.1007/s13244-012-0212-x.

Types of cancer treatment. National Cancer Institute (NIH) website. Accessed May 29, 2019.

Wong HH, Hatcher HM, Benson C, et al. Desmoplastic small round cell tumour: characteristics and prognostic factors of 41 patients and review of the literature. Clin Sarcoma Res. 2013;3:14. doi: 10.1186/2045-3329-3-14.

Xu H, Cheng M, Guo H, Chen Y, Huse M, Cheung N-K. Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody. Cancer Immunol Res. 2015;3(3):266-277. doi: 10.1158/2326-6066.CIR-14-0230-T.